

FY2026 Financial Results

Livingstone Health rationalised operations and reports higher revenues

- ***Reports revenues of S\$29.3 million (an increase of 5.9% from FY2025), demonstrating consistent growth trajectory for 2 consecutive years***
- ***Rationalised the Group's operations – invested in specialist and general surgery clinics; closed underperforming Ardennes health screening centre; and further improved operational efficiencies***
- ***Posts FY2026 Adjusted Net Profit of S\$608,000 (excluding losses and non-recurring expenses due to closure of Ardennes); and generated net operating cash flows of S\$3.1 million for FY2026***

Singapore, 26 May 2026 – Livingstone Health Holdings Limited (“Livingstone Health” or the “Company”, together with its subsidiaries, the “Group”) today reported its unaudited financial results for the financial year ended 31 March 2026 (“FY2026”).

FINANCIAL HIGHLIGHTS OF THE GROUP'S UNAUDITED RESULTS:

Financial year ending 31 March	FY2025 S\$'000	FY2026 S\$'000	Change %
Revenue	27,648	29,288	5.9
Profit attributable to Owners of the Company (“Net Profit”)	557	223	(60.0)
Adjusted profit attributable to Owners of the Company (excluding Ardennes' losses and non-recurring expenses due to closure) (“FY2026 Adjusted Net Profit”)	NA	608	NA

NA: Not applicable

FY2026 Financial Results

The Group reported another year of steady revenue growth, with revenue increasing 5.9% to S\$29.3 million in FY2026 from S\$27.6 million in the financial year ended 31 March 2025 (“FY2025”).

During the year, the Group closed the underperforming Ardennes health screening centre (“Ardennes”), as part of the Group's strategic decision in rationalising its operations while optimising its healthcare network. In line with the higher revenue, operating costs increased as a result of higher costs of sales and employee benefit expenses given expansion of the Primary Healthcare clinical team. There were also non-recurring costs associated with closure of Ardennes' operation, including reinstatement costs, write-offs and losses arising from the disposal of related medical assets.

Against this backdrop, the Group recorded a Net Profit of approximately S\$223,000 for FY2026. Excluding the losses and non-recurring expenses relating to the discontinued Ardennes' operations, the Group's FY2026 Adjusted Net Profit would have been approximately S\$608,000.

The Group also generated a net operating cash flows of S\$3.1 million during the year, as supported by better working capital management.

As at 31 March 2026, the Group maintained a healthy financial position with net assets attributable to owners of the Group of S\$6.9 million, including cash and cash equivalents of S\$2.4 million.

Business Commentary

Dr. Wilson Tay, Executive Director and CEO of Livingstone Health, shared: "We continue to invest in and focus on retaining our medical doctors and healthcare talent base, which has been instrumental in sustaining the Group's revenue growth. We closed the underperforming Ardennes, streamlined and rationalised our operations, as part our efforts to further improve our operational efficiency.

We invested in an endocrinology specialist clinic, and a colorectal and general surgery clinic, as announced in April 2025 and December 2025 respectively. In March 2026, we acquired another primary care clinic after expanding our PMG network over the last two financial years. These initiatives aim to further enhance its healthcare ecosystem through broader patient outreach and enhanced cross-referral networks across its various medical disciplines while monitoring its supply chain related costs."

Due to the on-going geopolitical tensions and inflationary pressures, the Group remains cautious of the business outlook as the operating environment continues to be challenging with rising business costs.

In FY2026, the Group secured additional term loan facilities from two regional banks amounting to an aggregate of S\$4.0 million, increasing its total available banking facilities to S\$7.0 million, which could support the Group's potential acquisition opportunities and working capital requirements.

– End –

About Livingstone Health

Livingstone Health Holdings Limited ("**Livingstone Health**" and together with its subsidiaries, the "**Group**") is a Singapore-based multidisciplinary healthcare group whose core competencies include Specialist Healthcare and Primary Healthcare.

The name "Livingstone" is inspired by the succulent plant Lithops, also known as "living stones". They symbolise the Group's resilience, growth and determination to be recognised as a trusted integrated healthcare provider for patients, as well as a centre of excellence for growth opportunities for medical professionals.

The Group currently operates 22 clinics with 24 medical specialists and practitioners, including a medical aesthetics clinic and a podiatry clinic situated in convenient and accessible locations throughout Singapore. It also provides healthcare consultancy services within the region.

For more information, please visit www.livingstonehealth.com.sg.



Media & Investor Contact Information

Wong Qingyuan
Chief Financial Officer
217 Henderson Road, #01-09 Henderson Industrial Park, Singapore 159555
+65 6932 7721 | Email: ir@livingstonehealth.com.sg

This press release has been reviewed by the Company's sponsor, SAC Capital Private Limited (the “**Sponsor**”). This press release has not been examined or approved by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Lee Khai Yinn (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-01, AIA Tower, Singapore 048542.